Educational Wellness Information Only
This platform provides peer-reviewed research summaries and educational content about peptides for wellness and optimization purposes. Nothing on this site is intended as medical advice, diagnosis, or treatment. We do not claim any peptide can diagnose, treat, cure, or prevent any disease. Always consult a licensed healthcare provider before beginning any wellness protocol.
Statements on this site have not been evaluated by the FDA. Compounded preparations are subject to applicable state and federal regulations. Availability and eligibility vary.
CJC-1295 vs GHRP-2
An educational, source-based comparison of CJC-1295 and GHRP-2 — how each peptide works, what it's researched for, and what to know before going deeper.
A synthetic analog of growth hormone-releasing hormone (GHRH). The non-DAC version has a short half-life that preserves pulsatile GH release, while DAC variants extend the half-life via albumin binding. Research focuses on stimulating endogenous GH and IGF-1 production via the pituitary.
- Endogenous GH pulse amplitude
- IGF-1 elevation
- Body composition in adult GH-deficient research
- Sleep architecture (slow-wave sleep)
- • GH-axis manipulation may affect glucose tolerance.
- • Banned in competitive sport (WADA).
- • Requires physician oversight in any therapeutic context.
A synthetic hexapeptide that activates the ghrelin/GHS-R1a receptor, stimulating endogenous GH release. Compared to Ipamorelin, GHRP-2 produces a stronger GH pulse but also modestly elevates cortisol, prolactin, and appetite.
- GH release in adult GH deficiency
- Appetite stimulation in cachexia models
- Diagnostic GH stimulation testing
- • Not FDA-approved.
- • Less receptor-selective than Ipamorelin; expect appetite and cortisol effects.
- • Prohibited by WADA.
Trial-evidence rating
Educational grade reflecting how many peer-reviewed studies and FDA actions we cite for each peptide. Not a clinical recommendation.
Two cited studies; independent replication needed.
Early-stage research; conclusions are tentative.
Study-by-study comparison
| Peptide | Study | Source | Year | Summary |
|---|---|---|---|---|
| CJC-1295 | Sustained pharmacological GH activity in healthy adults via DAC technology | Journal of Clinical Endocrinology & Metabolism | 2006 | Established prolonged GH/IGF-1 elevation from single subcutaneous doses. |
| CJC-1295 | GHRH analogs and the GH-IGF-1 axis | Endocrine Reviews | 2011 | Mechanistic review of GHRH-analog pharmacology. |
| GHRP-2 | GHRP-2 stimulates GH release in healthy and GH-deficient adults | Journal of Clinical Endocrinology & Metabolism | 1997 | Established robust GH response after subcutaneous administration. |
Side-effect & safety grid
- GH-axis manipulation may affect glucose tolerance.
- Banned in competitive sport (WADA).
- Requires physician oversight in any therapeutic context.
- Not FDA-approved.
- Less receptor-selective than Ipamorelin; expect appetite and cortisol effects.
- Prohibited by WADA.
Educational summary of considerations reported in research literature — not a complete list of adverse events. Discuss with a licensed clinician before any use.
CJC-1295 vs GHRP-2 — Key differences
- Class: CJC-1295 is classified as Growth Hormone Axis, while GHRP-2 is Growth Hormone Axis.
- Primary research focus: CJC-1295 — endogenous gh pulse amplitude; GHRP-2 — gh release in adult gh deficiency.
- Tag: Growth hormone vs Growth hormone.